Search Bar & Filters
Found 49 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are studying DB-1303BNT323, a biological drug, in a Phase 12a trial to evaluate its safety and tolerability in adults with advanced or metastatic malignant solid tumors that express HER2. The trial focuses on patients whose tumors are refractory to standard treatments or have no available standard options. This first-in-human study includes both a dose-escalation phase to find the maximum tolerated dose and a dose-expansion phase to further assess safety and explore efficacy in selected tumors. Participants receive DB-1303BNT323 intravenously once every three weeks at various dose levels, including a randomized comparison of doses during some expansion cohorts. Additional treatments may include ritonavir or itraconazole to assess drug interactions, and in some cases, DB-1303BNT323 is combined with Pertuzumab. The study is open-label and multicenter, with dosing continuing according to the protocols schedule. During the trial, participants undergo regular assessments including safety monitoring for adverse events, dose-limiting toxicities, and serious adverse events up to about one year post-treatment. Researchers measure tumor response using RECIST 1.1 criteria and evaluate pharmacokinetics and pharmacodynamics. Organ function, heart performance, and life expectancy are also monitored throughout this period. The estimated study completion is in October 2027.
Actively Recruiting
Researchers are studying the safety, tolerability, and effectiveness of elecoglipron alone or combined with dapagliflozin compared to placebo in adults with type 2 diabetes mellitus T2DM who are not well controlled with lifestyle changes or other glucose-lowering medications. This Phase III trial aims to better understand how these treatments impact blood sugar control and other health measures. Participants will be randomly assigned to one of four groups elecoglipron at dose level 1 with dapagliflozin placebo, elecoglipron at dose level 2 with dapagliflozin placebo, elecoglipron at one of the studied doses combined with dapagliflozin, or matching placebos for both drugs. All medications are taken orally once daily. The study lasts 40 weeks, during which participants receive their assigned treatment and are monitored. During the study, participants will undergo regular assessments including measurements of blood sugar control HbA1c, body weight, and blood pressure from baseline to Week 40. Researchers will also track the achievement of specific blood sugar targets, weight loss percentages, and the time before needing additional diabetes medication. Safety and tolerability will be monitored throughout the treatment period. The total participation duration is approximately 40 weeks.
Actively Recruiting
Researchers are evaluating elecoglipron, a drug administered orally once daily, for adults with type 2 diabetes mellitus T2DM who also have impaired kidney function and are receiving background treatment with dapagliflozin 10 mg, a sodium-glucose cotransporter 2 inhibitor SGLT2i. This phase III, randomized, double-blind study aims to assess the efficacy, safety, and tolerability of elecoglipron compared with placebo in this population, who are also on other glucose-lowering medications. Participants will be randomly assigned to receive either elecoglipron at one of two dose levels or a placebo, all given orally once daily alongside their background dapagliflozin treatment. The study uses a parallel-group design and will continue for 40 weeks, during which participants treatment adherence and response will be monitored closely. Throughout the study, participants will undergo regular assessments including measurements of hemoglobin A1c HbA1c from baseline to week 40, body weight, blood pressure, and fasting plasma glucose. Researchers will also track the time to initiation of any rescue medication and monitor for any hypoglycemic events. Safety and tolerability will be continuously evaluated during this period to understand the overall impact of elecoglipron compared to placebo.
Actively Recruiting
Bladder cancer is a common and serious tumor that originates from the bladders lining, with the majority being non-muscle invasive bladder cancer NMIBC. NMIBC has a high recurrence rate even after initial treatment, making postoperative bladder perfusion chemotherapy important to prevent tumor return. This research evaluates the use of patient-derived bladder cancer organoids to test drug sensitivities and guide individualized chemotherapy, aiming to improve treatment effectiveness and reduce recurrence for bladder cancer patients. The study involves preparing bladder cancer organoids from tumor tissue collected during surgery. Researchers perform drug sensitivity testing on these organoids with various chemotherapeutic agents, including gemcitabine, pirenzolubicin, epirubicin, mitomycin, and doxorubicin. Based on organoid sensitivity results, patients receive bladder perfusion chemotherapy with either sensitive or non-sensitive drugs, or receive BCG vaccine infusions. Treatment schedules include induction perfusion weekly for 4 weeks and maintenance perfusion monthly for 11 months, or BCG infusions following an induction and maintenance regimen over one year. Participants undergo regular clinical assessments including cystoscopy, urine cytology, and imaging as needed to monitor tumor recurrence and progression over up to three years. Researchers analyze one-year and three-year tumor recurrence-free and progression-free survival rates among groups. The study monitors patient compliance, adverse events, and clinical outcomes to assess the value of organoid drug sensitivity testing in guiding personalized bladder cancer perfusion chemotherapy.
Actively Recruiting
Researchers are evaluating the efficacy and safety of ABP1011T tablets in participants with advanced solid tumors, including small cell lung cancer, esophageal cancer, cervical cancer, bladder cancer, and renal cell carcinoma. This open-label, multi-cohort Phase IIb study builds on prior safety and efficacy data from an earlier clinical trial. Priority enrollment is given to patients with small cell lung cancer who have failed at least two prior systemic therapies. Participants receive ABP1011T tablets orally once daily on an empty stomach with water, avoiding food for at least one hour before and after dosing. Treatment follows a continuous 21-day cycle, and the study includes multiple cohorts Cohort A focuses on small cell lung cancer patients, while Cohort B includes other advanced solid tumors. The study treatment is administered continuously throughout the trial. During the study, participants undergo regular assessments to monitor treatment effects and safety, including evaluations of tumor response using the objective response rate ORR over approximately two years. Secondary outcomes include duration of relief, progression-free survival, disease control rate, sustained response rate, overall survival, and treatment-related adverse events. Participants are monitored closely for up to two years to assess the impact of the study drug.
Actively Recruiting
Researchers are evaluating the efficacy and safety of ATG-022 compared to Investigators Choice treatment in participants with CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma who have received prior second-line systemic therapy. This Phase III, randomized, controlled, open-label study involves participants with unresectable locally advanced or metastatic disease who have progressed after at least second-line and no more than fourth-line systemic therapy. The study is based on positive earlier data and aims to compare ATG-022 monotherapy with commonly used chemotherapy options. Participants receive either ATG-022 monotherapy at a dose of 1.8 mgkg every 21 days one cycle or Investigators Choice chemotherapy, which includes either Docetaxel or Irinotecan. Docetaxel is administered at 75-100 mgm every 21 days, while Irinotecan is given at 125 mgm on days 1 and 8 every 21 days. The study uses a parallel design to compare these two treatment regimens. Throughout the trial, participants undergo tumor assessments at baseline and then every 6 weeks during treatment, followed by less frequent evaluations after 12 and 24 months until disease progression or death. Survival follow-up occurs every 3 months until death or study end. Researchers measure progression-free survival, overall survival, objective response rate, disease control rate, and duration of response. Laboratory tests and physical examinations are conducted to monitor organ function and safety. Participants remain in the study until disease progression, death, or study completion, with ongoing monitoring of their health.
Actively Recruiting
Researchers are evaluating the efficacy and safety of GB491 combined with Letrozole compared to placebo combined with Letrozole in treating patients with hormone receptor-positive HR and human epidermal growth factor receptor 2-negative HER2- locally advanced or metastatic breast cancer. This study focuses on patients who have not previously received systemic antitumor therapy for this condition and aims to provide new treatment insights. Participants are randomly assigned to one of two groups one receives GB491 at 150 mg orally twice daily along with Letrozole 2.5 mg orally once daily, while the other receives a placebo twice daily with the same Letrozole dose. Treatment cycles last 28 days, and the study is designed as a randomized, double-blind, placebo-controlled phase III trial. During the study, participants will be closely monitored for progression-free survival assessed by investigators using RECIST v1.1 criteria over approximately 60 months. Additional measures include overall survival, response rates, duration of response, disease control rates, clinical benefit rates, and the frequency and severity of adverse events. Regular assessments ensure safety and treatment adherence throughout the study period.
Actively Recruiting
Acute ischemic stroke AIS is a serious condition caused by a sudden blockage of blood flow to part of the brain due to a clot forming in or traveling to brain vessels. This trial evaluates TAK-755, a study drug, to assess its safety and how well adults with AIS tolerate it. The study also examines whether TAK-755 can help improve participants daily functioning and reduce stroke symptom severity compared to a placebo, which looks like the drug but contains no medicine. Participants will receive a single intravenous infusion of either TAK-755 or a matching placebo on Day 1. This study includes two parts, Part A and Part B, with participants randomly assigned to receive TAK-755 or placebo in either part. After the infusion, all participants will continue to receive standard stroke care as per hospital practice, with health monitored for up to 90 days. Throughout the study, participants will be followed for about three months to monitor their health, including checking for any bleeding complications within 120 hours after treatment. Researchers will assess stroke severity, recovery, and brain imaging outcomes at multiple time points, including 24 hours, 72 hours, and 90 days. Safety evaluations will include monitoring adverse events, vital signs, blood tests, and antibody responses. The goal is to gather detailed information on how TAK-755 affects stroke recovery and participant safety over this period.
Actively Recruiting
Researchers are evaluating whether tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after the person was last seen well. This study focuses on people who had a stroke caused by a clot blocking a brain blood vessel and have imaging showing brain tissue that can still be saved. Participants are excluded if they are planned for a procedure to remove the clot. Participants are randomly placed into two groups. One group receives a single intravenous injection of tenecteplase, while the other group receives standard medical care. The trial compares these treatments to see if tenecteplase improves recovery when given later than the usual 4.5-hour window after stroke onset. Participants stay in the study for about three months, including roughly one week in the hospital. They undergo seven clinical visits or exams, with the last two likely done remotely from home. Doctors assess recovery using a scale that measures disability and dependence in daily life. They also monitor health and any side effects to compare outcomes between the two groups.
1-10 of 49
1